MODULATION OF 2'5' OLIGOADENYLATE SYNTHETASE (2,5A)ACTIVITY AND INTERFERON (IFN) BINDING IN PATIENTS (PTS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) UNDERGOING IFN THERAPY

被引：0
|
作者：
ROSENBLUM, MG [1 ]
MAXWELL, BL [1 ]
TALPAZ, M [1 ]
GUTTERMAN, JU [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,HOUSTON,TX 77030
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1984年 / 25卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [1] INDUCTION OF 2'-5' OLIGOADENYLATE SYNTHETASE DURING INTERFERON TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
    MORITZ, T
    WEISSMANN, B
    GRUNEWALD, B
    HUST, H
    KUMMER, G
    NIEDERLE, N
    MOLECULAR BIOTHERAPY, 1992, 4 (02) : 97 - 102
  • [2] Treatment of patients with multiply myeloma (MM) and chronic myelogenous leukemia (CML) with alpha-2 interferon (IFN).
    Bessmeltsev, SS
    Rukavitsyn, OA
    Abdulkadyrov, KM
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 711 - 711
  • [3] Association of hla phenotype and response to interferon alfa (IFN) in patients with chronic myelogenous leukemia (CML).
    Cortes, J
    Kantarjian, H
    Talpaz, M
    BLOOD, 1995, 86 (10) : 1739 - 1739
  • [4] Treatment of Ph+ chronic myelogenous leukemia (CML) with interferon alfa 2B R(IFN)
    Murro, H
    Bezares, R
    Longordo, F
    Fuchs, CR
    Saidon, G
    Diaz, A
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 813 - 813
  • [5] Interferon (IFN) therapy combined with nonsteroid antiinflammatory drugs (AINS) does not induce a significant increase of 2'5' oligoadenylate synthetase (2'5' AS) activity in patients with chronic hepatitis C.
    Maynard, M
    Chousterman, S
    Baud, M
    Hicham, T
    Hamici, L
    Zarski, JP
    HEPATOLOGY, 1996, 24 (04) : 1106 - 1106
  • [6] Pilot study of interferon alpha receptor (IFN alpha R) expression in patients with chronic myelogenous leukemia (CML).
    Spielberger, R
    Snyder, D
    Forman, SJ
    Niland, J
    Nunez, R
    Domanski, PI
    Colamonici, O
    BLOOD, 1995, 86 (10) : 2100 - 2100
  • [7] Effect of interferon-alpha (IFN-A) therapy on bone marrow (BM) fibrosis in chronic myelogenous leukemia (CML)
    Wilhelm, M
    Ramos, CM
    OBrien, S
    Pierce, S
    Keating, M
    Talpaz, M
    Kantarjian, H
    BLOOD, 1996, 88 (10) : 3537 - 3537
  • [8] Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: Relationship to the antiviral effect of IFN-alpha
    Pawlotsky, JM
    Hovanessian, AG
    RoudotThoraval, F
    Robert, N
    Bouvier, M
    Babany, G
    Duval, J
    Dhumeaux, D
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) : 320 - 324
  • [9] Suppression of clonal evolution in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on interferon alfa therapy (IFN-A) therapy.
    Cortes, J
    Kantarjian, H
    OBrien, S
    Beran, M
    Estey, E
    Koller, C
    Andreeff, M
    Kornblau, S
    Keating, M
    Freireich, EJ
    Talpaz, M
    BLOOD, 1996, 88 (10) : 918 - 918
  • [10] Early treatment decisions with interferon alpha (IFN-A) therapy in early chronic phase chronic myelogenous leukemia (CP-CML).
    Sacchi, S
    Kantarjian, K
    Smith, T
    OBrien, S
    Pierce, S
    Kornblau, S
    Beran, M
    Keating, M
    Talpaz, M
    BLOOD, 1997, 90 (10) : 2303 - 2303
12345